3-year-data of combined navigated laser photocoagulation (Navilas) and intravitreal ranibizumab compared to ranibizumab monotherapy in DME patients.
Tina Rike HeroldJulian LangerEfstathios VounotrypidisMarcus KerntRaffael LieglSiegfried G PriglingerPublished in: PloS one (2018)
Combination of navigated laser and ranibizumab achieved BCVA gains equivalent to anti-VEGF monotherapy. These results could be maintained through month 36. Required injections were 2.0 injections lower in year 1 and further 1.3 times fewer in year 2 and 3 in the combination group compared to monotherapy. Adding navigated laser photocoagulation to intravitreal anti-VEGF therapy may still represent a superior therapeutic approach to DME patients.
Keyphrases
- diabetic retinopathy
- end stage renal disease
- vascular endothelial growth factor
- chronic kidney disease
- age related macular degeneration
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- endothelial cells
- open label
- clinical trial
- machine learning
- stem cells
- mass spectrometry
- high speed
- optical coherence tomography
- bone marrow
- high resolution
- platelet rich plasma
- data analysis
- ultrasound guided